E

Things we need to think about ahead of ASCO17

A fireside chat with a leading KOL involved in cancer research on resistance.

May 16, 2017
E

Going Beyond PARP in DNA Damage Repair

A look a one company's approach to DDR and potential combination opportunities in this niche

May 9, 2017
E

On Gritstone and neoantigens

A look at a promising biotech in the neoantigen space - what's their approach and how might it fare?

May 4, 2017
E

What do we know about Resistance to Checkpoints in Lung Cancer?

Expert interview at AACR17 with Dr Julie Brahmer on lung cancer immunotherapy resistance and preview of ASCO17 abstracts

April 20, 2017
E

Do Exosomes Matter?

With 'liquid biopsies' on the rise, we take a look at another potential candidate that could be useful - exploring exosomes.

May 2, 2017
E

How do we get cancer immunotherapy to work in Prostate Cancer?

A candid look at new approaches being explored in cold tumours using prostate cancer as an example

May 1, 2017
E

BSB Mailbag on ROS1, ALK and TRK inhibitors

BSB Reader Mailbag on TRK/ROS1/ALK inhibitors

April 28, 2017
E

Can Jonathan Lim ignite the TRK oncology space?

An interview with Dr Jonathan Lim, Ignyta on TRK/ROS/ALK inhibition

April 26, 2017
E

Can AZN take immuno-oncology to the next level?

Through the keyhole with a look at AZN and MedImmune's IO portfolio

April 25, 2017
E

Potential of CAR T cell therapy targeting Glioblastoma

Encouraging new developments in GBM with a novel CAR T cell therapy

April 18, 2017
E

Overcoming Cancer Immunotherapy Resistance

How do we overcome resistance to cancer immunotherapies? Here, we have an in-depth interview with a thought leader in this space.

April 17, 2017
E

Dan Chen outlines his vision for the Future of Cancer Immunotherapy at AACR17

Dr Daniel Chen from Roche/Genentech shares his vision for the future of cancer immunotherapy at AACR17.

April 13, 2017
E
AACR17 audience

Five Emerging Cancer Research Trends at AACR17

Five emerging cancer research trends we picked up at AACR17 that you should be aware of.

April 11, 2017
E

What does atezolizumab TNBC data presented at AACR17 tell us about breast cancer immunotherapy?

Interview with Professor Peter Schmid, Barts Cancer Institute.

April 10, 2017
E

Corvus CPI-444 Data Disappoints at AACR 2017

Commentary on Tuesday at 2017 AACR annual meeting in Washington DC.

April 5, 2017
E

A Busy Monday at AACR 2017

Commentary on Monday at the 2017 AACR annual meeting.

April 4, 2017
E

Sunday at AACR 2017 annual meeting

Commentary on Sunday at the 2017 AACR annual meeting

April 3, 2017
E

Reflections on Saturday at AACR17

Highlights from Day 1 at AACR17

April 1, 2017
E

AACR 2017 Preview 10

A look at some of the key sessions featuring checkpoint blockade at the AACR 2017 annual meeting

March 29, 2017
E

AACR 2017 Preview 9

A comprehensive review of the key abstracts in the CAR T cell therapy niche and hints of the latest emerging trends

March 23, 2017
E

AACR 2017 Preview 8

A look at how research into transcription factors, super enhancers, chromatin regulation and broom/chromodomains is changing the way we look at cancer

March 22, 2017
E

AACR 2017 Preview 7

With increasing competition in the CDK4/6 space in HR+ HER2- metastatic breast cancer, how are things shaping up?

March 21, 2017
E

AACR 2017 Preview 6

A look at a new area of immune-oncology that looks set to be in the consciousness more over the next few years

March 15, 2017
E

AACR 2017 Preview 5

PARP! PARP! What's hot in ovarian cancer at SGO and AACR?

March 13, 2017
E

AACR 2017 Preview 4

Overcoming immune suppression in the tumour microenvironment

March 9, 2017
E

AACR 2017 Preview 3

Washington Monument After exploring a mechanistic approach and a tumour type as part of our AACR annual…

March 8, 2017
E

AACR 2017 Preview 2

A look at some recent clinical data and what we can learn from the new data expected at AACR in DC

March 7, 2017
E

AACR 2017 Preview 1

The first of our strategic and thematic AACR Previews for the 2017 annual meeting is here

March 6, 2017